摘要:
Antiviral activity is exhibited by compounds having the formula ##STR1## and their pharmaceutically acceptable salts. R.sub.1 is ##STR2## R.sub.2 is hydrogen, --PO.sub.3 H.sub.2, ##STR3## wherein R.sub.3 is hydrogen, alkyl, substituted alkyl, or aryl, and R.sub.4 is alkyl.
摘要翻译:抗病毒活性由具有式“IMAGE”1的化合物及其药学上可接受的盐显示。 R 1是氢,-PO 3 H 2,其中R 3是氢,烷基,取代的烷基或芳基,且R 4是烷基。
摘要:
The present invention relates to novel cyclopropane derivatives represented by Formula I: wherein R represents a hydrocarbon group containing 1-20 carbon atoms or an ester containing 1-20 carbon atoms;wherein R′ represents a C1-C6 acyclic carboxylic acid ester, a C4-C6 cyclic carboxylic acid ester or —OR″, and R″ is selected from the group consisting of H, a C1-C6 acyclic hydrocarbon group, a C3-C6 carbocyclic ring and a C4-C5 heterocyclic ring; andwherein the composition is selected from the group consisting of a flavor composition and a fragrance composition.
摘要:
The present invention is directed to novel substituted cyclopropane ethers compounds of the general formulae selected from the group consisting of wherein R represent a hydrogen or a straight, branched, or cyclic hydrocarbon moiety consisting of less then 15 carbon atoms and containing single and/or double bonds and R1 represents a methyl or ethyl group.
摘要翻译:本发明涉及新型的取代环丙烷醚化合物,其通式选自其中R表示氢或直链,支链或环状烃部分,由少于15个碳原子组成且含有单和/或双 R 1表示甲基或乙基。
摘要:
The present invention is directed to novel substituted cyclopropane ethers compounds of the general formulae selected from the group consisting of wherein R and R1 independently represent a hydrogen or a straight, branched, or cyclic hydrocarbon moiety consisting of less then 15 carbon atoms and containing single and/or double bonds.
摘要:
A titanium catalyst for reaction between a compound having a carbon-carbon unsaturated bond and a compound having an electrophilic functional group or an electrophilic reagent, said titanium catalyst being composed of a titanium compound represented by the formula (1) below TiX1X2X3X4 (1) (where X1, X2, X3, and X4 denote independently a halogen atom, C1-20 alkoxyl group, aralkyloxy group, aryloxy group, or —NRxRy group (where Rx and Ry denote independently a C1-20 alkyl group or aralkyl group), and any two of X1, X2, X3, and X4 may form a ring.) and a Grignard reagent represented by the formula (2) below in a molar amount 1.5-2.5 times as much as the titanium compound. R1MgX5 (2) (where R1 denotes a C2-10 alkyl group having a hydrogen atom at the β position and X5 denotes a halogen atom.) The titanium catalyst of the present invention activates the carbon-carbon unsaturated bond, which has a comparatively low reactivity, thereby catalyzing the reaction with an electrophilic functional group. It is inexpensive and industrially advantageous. When applied to reaction between a compound having a carbon-carbon unsaturated bond and an electrophilic functional group, it yields industrially a variety of adducts of a compound having a carbon-carbon unsaturated bond and a compound having an electrophilic functional group, and it also yields a variety of intramolecular adducts of a compound having a carbon-carbon unsaturated bond and an electrophilic functional group in the same molecule.
摘要:
Antiviral activity is exhibited by compounds having the formula ##STR1## and its pharmaceutically acceptable salts wherein R.sub.1 is ##STR2## wherein R.sub.2 is hydrogen, methyl, fluoro, chloro, bromo, iodo, hydroxy or amino; or trifluoromethyl; R.sub.5 is alkyl; R.sub.6 is hydrogen, alkyl, substituted alkyl, or aryl; and R.sub.7 and R.sub.8 are independently hydrogen, ##STR3##
摘要:
Antiviral activity is exhibited by compounds having the formula ##STR1## and its pharmaceutically acceptable salts wherein R.sub.1 is ##STR2## R.sub.6 is hydrogen, alkyl, substituted alkyl, or aryl; and R.sub.7 and R.sub.8 are independently hydrogen, ##STR3##
摘要:
The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams from the intermediates. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.
摘要:
A first aspect of the present invention describes a compound selected from group consisting of: wherein R is either H, C(O)RA, or C(O)NHCH(X)COOH; provided that X is a C2-C6 alkyl, or a C3-C8 cycloalkyl and RA is a C1-6 alkyl or aryl; These compounds are used to make Compound A